Renaissance Technologies’s Benitec Biopharma BNTC Stock Holding History

Renaissance Technologies’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,228	Closed	-$47K	–	3923
2023 Q1	$47K	Sell	13,228 -8,862	-40%	-$36.1K	﹤0.01%	3674
2022 Q4	$64K	Buy	22,090 +15,006	+212%	+$50.8K	﹤0.01%	3744
2022 Q3	$45K	Buy	+7,084	New	+$90K	﹤0.01%	3781
2021 Q3	–	Sell	-2,512	Closed	-$181K	–	3483
2021 Q2	$181K	Buy	+2,512	New	+$197K	﹤0.01%	3266
2021 Q1	–	Sell	-2,980	Closed	-$152K	–	3322
2020 Q4	$152K	Buy	+2,980	New	+$148K	﹤0.01%	3197
2019 Q4	–	Sell	-54	Closed	-$10K	–	3502
2019 Q3	$10K	Hold	54	–	–	﹤0.01%	3390
2019 Q2	$10K	Hold	54	–	–	﹤0.01%	3508
2019 Q1	$27K	Hold	54	–	–	﹤0.01%	3385
2018 Q4	$21K	Hold	54	–	–	﹤0.01%	3323
2018 Q3	$32K	Hold	54	–	–	﹤0.01%	3303
2018 Q2	$27K	Hold	54	–	–	﹤0.01%	3208
2018 Q1	$44K	Hold	54	–	–	﹤0.01%	3307
2017 Q4	$41K	Buy	+54	New	+$37.8K	﹤0.01%	3271

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies's BNTC Position: Q2 2023 in Review

Renaissance Technologies sold out of Benitec Biopharma (BNTC) in Q2 2023, closing a stake of 13,228 shares — an estimated $47K sold.

Renaissance Technologies first reported a position in BNTC in Q4 2017 and held it in 13 quarters. The position peaked at $181K in Q2 2021. 17 funds tracked by Wall St. Rank hold BNTC as of Q2 2023.

Renaissance Technologies reported no remaining Benitec Biopharma position as of Q2 2023 after selling out during the quarter.
Renaissance Technologies sold 13,228 Benitec Biopharma shares in Q2 2023, an estimated $47K.
Renaissance Technologies first reported a position in Benitec Biopharma in Q4 2017 and held it in 13 quarters.
Renaissance Technologies's Benitec Biopharma position peaked at $181K in Q2 2021.
17 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.